| Renal Cell Carcinoma

Inlyta vs Zirabev

Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.

Deep comparison between: Inlyta vs Zirabev with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsZirabev has a higher rate of injection site reactions vs Inlyta based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Zirabev but not Inlyta, including UnitedHealthcare

Category

Inlyta

Zirabev

At A Glance

RouteOral

FrequencyTwice daily

ClassVEGFR tyrosine kinase inhibitor

RouteIV infusion

FrequencyEvery 2-3 weeks

ClassVEGF inhibitor

Indications

Renal Cell Carcinoma

Metastasis from malignant neoplasm of colon and/or rectum
Non-Small Cell Lung Carcinoma
Glioblastoma
Renal Cell Carcinoma
Cervix carcinoma
Malignant neoplasm of ovary
Fallopian Tube Carcinoma
Primary Peritoneal Cancer

Dosing

Renal Cell Carcinoma (first-line, with avelumab) 5 mg orally twice daily combined with avelumab 800 mg IV every 2 weeks; dose escalation may be considered at intervals of 2 weeks or longer.

Renal Cell Carcinoma (first-line, with pembrolizumab) 5 mg orally twice daily combined with pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks IV; dose escalation may be considered at intervals of 6 weeks or longer.

Renal Cell Carcinoma (second-line, single agent) Starting dose 5 mg orally twice daily approximately 12 hours apart, with or without food; doses may be increased to 7 mg or 10 mg twice daily based on tolerability, or reduced to 3 mg or 2 mg twice daily for adverse reactions.

Metastasis from malignant neoplasm of colon and/or rectum 5 mg/kg IV every 2 weeks with bolus-IFL; 10 mg/kg IV every 2 weeks with FOLFOX4; 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy after progression on a first-line bevacizumab product-containing regimen.

Non-Small Cell Lung Carcinoma 15 mg/kg IV every 3 weeks in combination with carboplatin and paclitaxel.

Glioblastoma 10 mg/kg IV every 2 weeks.

Renal Cell Carcinoma 10 mg/kg IV every 2 weeks in combination with interferon alfa.

Cervix carcinoma 15 mg/kg IV every 3 weeks in combination with paclitaxel and cisplatin or paclitaxel and topotecan.

Malignant neoplasm of ovary, Fallopian Tube Carcinoma, Primary Peritoneal Cancer Stage III/IV following initial surgical resection: 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel for up to 6 cycles, followed by 15 mg/kg every 3 weeks as a single agent for up to 22 cycles. Platinum-resistant recurrent: 10 mg/kg IV every 2 weeks with paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg IV every 3 weeks with topotecan (every 3 weeks). Platinum-sensitive recurrent: 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel or carboplatin and gemcitabine for 6-10 cycles, followed by 15 mg/kg every 3 weeks as a single agent.

Contraindications

—

Drug Interactions

1120View drug interactions

231View drug interactions

Adverse Reactions

Most common (>=20%) Diarrhea, fatigue, hypertension, hepatotoxicity, hypothyroidism, decreased appetite, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, musculoskeletal pain, constipation

Serious Hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, hepatotoxicity

Postmarketing Arterial aneurysms, dissections, and rupture (including aortic)

Most common (>10%) Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis.

Serious Gastrointestinal perforations and fistulae, surgery and wound healing complications, hemorrhage, arterial thromboembolic events, venous thromboembolic events, hypertension, posterior reversible encephalopathy syndrome, renal injury and proteinuria, infusion-related reactions, ovarian failure, congestive heart failure.

Postmarketing Polyserositis, pulmonary hypertension, mesenteric venous occlusion, gastrointestinal ulcer, intestinal necrosis, anastomotic ulceration, pancytopenia, gallbladder perforation, osteonecrosis of the jaw, renal thrombotic microangiopathy, nasal septum perforation, arterial aneurysms/dissections/rupture.

Pharmacology

Axitinib is a selective inhibitor of receptor tyrosine kinases including VEGFR-1, VEGFR-2, and VEGFR-3, which are implicated in pathologic angiogenesis, tumor growth, and cancer progression; VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse models.

Bevacizumab-bvzr binds VEGF and prevents its interaction with receptors Flt-1 and KDR on the surface of endothelial cells, inhibiting endothelial cell proliferation, new blood vessel formation, and metastatic disease progression.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Inlyta